The mechanism of action of DOACS is fundamentally different than VKA (such as warfarin). While more similar in action to heparins, including fondaparinux, important differences exist, as described below. Warfarin functions as an anticoagulant by diminishing the synthesis of functional vitamin K-dependent coagulation factors,
| INTRODUCTION
If a patient with a history of atrial fibrillation, taking the recom- 
| ANTICOAGULANT MECHANISM OF ACTION AND PROPOSED RELATIONSHIP TO THE APTT AND PT
Direct oral anticoagulants are a relatively new class of immediate acting, oral anticoagulant agents that function as direct inhibitors of thrombin (DTI) or activated factor X (FXa). They are administered for thromboprophylaxis in atrial fibrillation and prevention or treatment of venous thrombosis (VTE). 3 In 2016, the American Association of Chest Physicians recommended the use of DOACs over vitamin K antagonists (VKA) for the treatment of non-cancer-related VTE. 4 These agents are administered in fixed doses and do not require routine (episodic or frequent) monitoring. [5] [6] [7] [8] There may be occasions where it is advantageous to measure drug levels and this can be accomplished using methodologies other than a simple APTT or PT. 4, 9 The mechanism of action of DOACS is fundamentally different than VKA (such as warfarin). While more similar in action to heparins, including fondaparinux, important differences exist, as described An important differentiator from DOACS and limiting their anticoagulant potential is the fact that heparin, LMWH, and fondaparinux have catalytic activity against only the free form of the activated factor and not that factor bound in enzyme complexes or to fibrin. 13 In contrast, DOACS inhibit both free and bound activated factors. The activated factors bound in enzyme complexes are significantly (ie, 300 000×) more effective than the free form of the activated factors. 16 Given the difference in their ability to inactivate free vs bound factor and the impact this has on thrombin inhibition, direct FXa and thrombin inhibitors are believed to function as more effective anticoagulant agents. 13 Like LMWH and fondaparinux, DOACS (especially apixaban), may have little to no effect on screening coagulation assays despite having therapeutic plasma concentrations. 9, 17 The basis of this unresponsiveness, while partially related to reagent composition, is not fully understood. This poor correlation of APTT and PT prolongation to the physiologic level of DOAC anticoagulation may be related to the fact that clot formation in APTT and PT reactions requires only about 3% of the total thrombin that is generated. 18 The laboratorybased APTT and PT cascades therefore do not accurately reflect the clotting process as it occurs in vivo. As both direct Xa and thrombin inhibitors function as anticoagulants by effectively inhibiting thrombin generation, the APTT and PT are limited in assessing total thrombin inhibition and therefore the level of in vivo DOAC anticoagulation.
| The relationship of DOACS to APTT and PT: the data
It is well documented that there is often a poor correlation between plasma concentration of DOACS and prolongation of the APTT and PT. 3, 9, 17, 19, 20 Furthermore, numerous studies have demonstrated that APTT and PT reagents demonstrate variable responsiveness to DOAC presence. 3, 9, 17, 19, 20 A number of studies have reported on the misprediction rate of the PT and PTT in patients on DOACS. 19, 20 The term misprediction is used when patients have on therapy DOAC concentrations with normal APTT and PT values. For dabigatran, looking at an array of different reagents, misprediction of the APTT has been reported to be in the 18% range and in the range of 30% for PT reagents.
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For rivaroxaban, published misprediction of the PT ranged from 10% to 52% and 31% to 59% for APTT depending on the reagent used.
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A recent 2016 review on the laboratory assessment of DOACS by Samuelson et al. 3 included 112 studies that reported a relationship between drug levels and coagulation assay results. In this study, the authors reported the following:
• For dabigatran, the degree of APTT prolongation varied across reagents and correlated poorly with drug concentration with normal APTT results seen with select reagents at low drug concentrations while the sensitivity of the PT/INR was low for dabigatran presence.
• For rivaroxaban and edoxaban, the degree of PT and APTT prolongation varied across reagents and while the PT and APTT tended to prolong in a concentration-dependent manner, overall the correlations were insufficiently sensitive.
• For apixaban, PT and APTT sensitivity was inadequate.
| The relationship of DOACS to APTT and PT: the potential for patient harm
An observational study investigating the awareness of APTT and PT unresponsiveness to DOAC therapy and the potential for patient harm was published by Olaiya in 2016. 1 In this study, a questionnaire that inquired about a patient who had been administered a therapeutic dose of a DOAC 12 hours previously, who had a slightly prolonged APTT and normal PT, and required an invasive procedure was sent to clinicians. This study unearthed a number of troubling findings including the fact that 12%-50% of the clinicians surveyed were unaware that rivaroxaban, dabigatran, and apixaban were anticoagulants.
When these clinicians were excluded from further questioning, 55%-85% of respondents, based on an electronic questionnaire, did not recognize when it was unsafe for the patient in question to proceed with an invasive procedure. Given this, in addition to the percentage of patients that cannot recite their medication list to caregivers, the potential for patient harm may be significant. • The APTT is not a global measure of anticoagulant therapies. A normal APTT does not ensure that a patient on anticoagulant therapy is hemostatically normal. Patients may have therapeutic plasma levels of a DOAC (as well as LMWH and fondaparinux) with a normal APTT, depending on the DOAC and the reagent used.
| Teaching points
• It is vital that laboratory scientists have a proactive role in clinician education and consultation, and laboratories should have the capacity to provide clinicians adequate tools for assessing DOAC presence and possibly concentration, should the need arise.
| CONCLUSION
In patients on DOAC prophylaxis or therapy, APTT and PT values do not reliably reflect plasma DOAC concentration. The APTT and PT/ INR can fall in the normal or near-normal range in a patient fully anticoagulated on one of the DOACS and this is most likely to occur with apixaban therapy. Clinicians must acknowledge that the APTT and PT can no longer be used as a general gauge of a patient's level of anticoagulation and hence bleeding risk. Clinicians will need to consider additional assays to screen for DOAC anticoagulant effect such as the thrombin time and chromogenic anti-Xa assay.
